ARTICLE | Company News
Proacta Therapeutics, Seattle Genetics deal
October 29, 2001 8:00 AM UTC
SGEN received exclusive worldwide rights from Proacta to a set of cytotoxic therapeutics that target the minor groove of DNA. SGEN will evaluate the products as single agents and in SGEN’s antibody-dr...